Jan Lichtenberg

Chief Executive Officer

Therapeutic Areas

Drug	Indication	Phase
Undisclosed MASH Program	Metabolic Dysfunction-Associated Steatohepatitis (MASH)	Discovery
Undisclosed Obesity Program	Obesity	Discovery